Adoptive immunotherapy of esablished pulmonary metastases with LAK cells and recombinant interleukin-2

James J. Mulé, Suyu Shu, Susan L. Schwarz, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

The activation of human peripheral blood leukocytes or murine splenocytes with interleukin-2 (IL-2) generated cells that were lytic in vitro for a variety of fresh tumor cells. The adoptive transfer of such lymphokine-activated killer (LAK) cells to mice with established pulmonary sarcoma metastases was highly effective in reducing the number (and size) ofthese tumor nodules when combined with repeated injections of recombinant IL-2. These findings provide a rationale for clinical trials of the infusion of human LAK cells generated with recombinant IL-2 as well as Phase I trials of the infusion of recombinant IL-2 systemically into humans.

Original languageEnglish (US)
Pages (from-to)1487-1489
Number of pages3
JournalScience
Volume225
Issue number4669
StatePublished - 1984
Externally publishedYes

Fingerprint

Adoptive Immunotherapy
Lymphokine-Activated Killer Cells
Interleukin-2
Neoplasm Metastasis
Lung
Adoptive Transfer
Sarcoma
Neoplasms
Leukocytes
Clinical Trials
Injections

ASJC Scopus subject areas

  • General

Cite this

Mulé, J. J., Shu, S., Schwarz, S. L., & Rosenberg, S. A. (1984). Adoptive immunotherapy of esablished pulmonary metastases with LAK cells and recombinant interleukin-2. Science, 225(4669), 1487-1489.

Adoptive immunotherapy of esablished pulmonary metastases with LAK cells and recombinant interleukin-2. / Mulé, James J.; Shu, Suyu; Schwarz, Susan L.; Rosenberg, Steven A.

In: Science, Vol. 225, No. 4669, 1984, p. 1487-1489.

Research output: Contribution to journalArticle

Mulé, JJ, Shu, S, Schwarz, SL & Rosenberg, SA 1984, 'Adoptive immunotherapy of esablished pulmonary metastases with LAK cells and recombinant interleukin-2', Science, vol. 225, no. 4669, pp. 1487-1489.
Mulé, James J. ; Shu, Suyu ; Schwarz, Susan L. ; Rosenberg, Steven A. / Adoptive immunotherapy of esablished pulmonary metastases with LAK cells and recombinant interleukin-2. In: Science. 1984 ; Vol. 225, No. 4669. pp. 1487-1489.
@article{da2e4ecf3d874456acddc71ebc693863,
title = "Adoptive immunotherapy of esablished pulmonary metastases with LAK cells and recombinant interleukin-2",
abstract = "The activation of human peripheral blood leukocytes or murine splenocytes with interleukin-2 (IL-2) generated cells that were lytic in vitro for a variety of fresh tumor cells. The adoptive transfer of such lymphokine-activated killer (LAK) cells to mice with established pulmonary sarcoma metastases was highly effective in reducing the number (and size) ofthese tumor nodules when combined with repeated injections of recombinant IL-2. These findings provide a rationale for clinical trials of the infusion of human LAK cells generated with recombinant IL-2 as well as Phase I trials of the infusion of recombinant IL-2 systemically into humans.",
author = "Mul{\'e}, {James J.} and Suyu Shu and Schwarz, {Susan L.} and Rosenberg, {Steven A.}",
year = "1984",
language = "English (US)",
volume = "225",
pages = "1487--1489",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "4669",

}

TY - JOUR

T1 - Adoptive immunotherapy of esablished pulmonary metastases with LAK cells and recombinant interleukin-2

AU - Mulé, James J.

AU - Shu, Suyu

AU - Schwarz, Susan L.

AU - Rosenberg, Steven A.

PY - 1984

Y1 - 1984

N2 - The activation of human peripheral blood leukocytes or murine splenocytes with interleukin-2 (IL-2) generated cells that were lytic in vitro for a variety of fresh tumor cells. The adoptive transfer of such lymphokine-activated killer (LAK) cells to mice with established pulmonary sarcoma metastases was highly effective in reducing the number (and size) ofthese tumor nodules when combined with repeated injections of recombinant IL-2. These findings provide a rationale for clinical trials of the infusion of human LAK cells generated with recombinant IL-2 as well as Phase I trials of the infusion of recombinant IL-2 systemically into humans.

AB - The activation of human peripheral blood leukocytes or murine splenocytes with interleukin-2 (IL-2) generated cells that were lytic in vitro for a variety of fresh tumor cells. The adoptive transfer of such lymphokine-activated killer (LAK) cells to mice with established pulmonary sarcoma metastases was highly effective in reducing the number (and size) ofthese tumor nodules when combined with repeated injections of recombinant IL-2. These findings provide a rationale for clinical trials of the infusion of human LAK cells generated with recombinant IL-2 as well as Phase I trials of the infusion of recombinant IL-2 systemically into humans.

UR - http://www.scopus.com/inward/record.url?scp=0021170244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021170244&partnerID=8YFLogxK

M3 - Article

C2 - 6332379

AN - SCOPUS:0021170244

VL - 225

SP - 1487

EP - 1489

JO - Science

JF - Science

SN - 0036-8075

IS - 4669

ER -